---
title: "44 Growth-stage Biotech Investors in the US (Nov 2026)"
last_updated: "2026-11-06"
rows: "44"
free_rows: "22"
source: "SEC filings"
canonical: "https://theinvestordatabase.com/lists/growth-biotech-investors-us/"
---

# 44 growth-stage biotech investors in the US

We list 44 growth-stage biotech investors in the US as of November 2026: each has an SEC filing on file, and the list was last checked on 6 Nov 2026. The cities with the most head offices on this list are New York (7), Menlo Park (3) and Boston (3).

- 44 investors
- 23 with a fund filing or dated deal in the last 12 months
- $100M median fund size on file (SEC Form D, 26 firms)
- 251 named decision-makers on file

## First 22 of 44 growth-stage biotech investors in the US

| Investor | Type | HQ | Stages (our research) | Focus (our research) | Latest fund or deal | Fund size | Checked | Profile |
|---|---|---|---|---|---|---|---|---|
| Longitude Venture Partners | VC firm | Menlo Park, CA | Growth | Biotech, Healthtech, Medtech | New deal, Jun 2026 | $600M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/longitude-venture-partners/ |
| MVM Partners LLP | VC firm | Boston, MA | Growth | Biotech, Healthtech, Medtech | Portfolio news, Jun 2026 | $1.0B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/mvm-partners-llp/ |
| JSTAR Capital | VC firm | Austin, TX | Growth | Biotech, Healthtech, AI, Fintech | New fund, Aug 2026 | $100M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/jstar-capital/ |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 2026-11-05 | https://theinvestordatabase.com/investors/madrona/ |
| NewVale Capital | VC firm | Boulder, CO | Growth | Biotech, Healthtech, Medtech | New fund, Oct 2026 | $250M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/newvale-capital/ |
| Audere | VC firm | Austin, TX | Growth | Biotech, Cybersecurity, AI, Robotics | New fund, Oct 2026 | $100M (SEC Form D, 2024) | 2026-11-04 | https://theinvestordatabase.com/investors/audere/ |
| Arcventis Health Partners | VC firm | New York, NY | Growth | Biotech, Healthtech, Medtech | New fund, Sep 2026 | $33M (SEC Form D, 2025) | 2026-11-04 | https://theinvestordatabase.com/investors/arcventis-health-partners/ |
| THP | VC firm | San Francisco, CA | Growth | Biotech, Healthtech, Industrial Tech, Medtech | Portfolio news, Apr 2026 | $79M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/thp/ |
| Eckuity Capital | VC firm | New York, NY | Growth | Biotech, Healthtech, Medtech | New fund, Jun 2026 | $300M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/eckuity-capital/ |
| BroadOak Capital Partners | VC firm | Bethesda, MD | Growth | Biotech, Healthtech, Industrial Tech, SaaS | Portfolio news, Apr 2026 | $11M (SEC Form D, 2021) | 2026-11-05 | https://theinvestordatabase.com/investors/broadoak-capital-partners/ |
| K5 Global | VC firm | Miami Beach, FL | Pre-seed, Growth, Any stage | Biotech, AI, Fintech, Healthtech | New fund, Oct 2026 | $10M (SEC Form D, 2026) | 2026-11-04 | https://theinvestordatabase.com/investors/k5-global/ |
| Signet Healthcare Partners | VC firm | New York, NY | Growth | Biotech, Industrial Tech, Developer Tools, Healthtech | Portfolio news, May 2025 | $300M (SEC Form D, 2022) | 2026-11-05 | https://theinvestordatabase.com/investors/signet-healthcare-partners/ |
| Agent Capital | VC firm | Waltham, MA | Seed, Growth | Biotech, Healthtech | New fund, Feb 2026 | $100M (SEC Form D, 2021) | 2026-11-04 | https://theinvestordatabase.com/investors/agent-capital/ |
| Andreessen Horowitz (a16z) | VC firm | Menlo Park, CA | Seed, Series A, Series B, Growth | Biotech, AI, Defense Tech, Healthtech | New fund, Aug 2026 |  | 2026-11-04 | https://theinvestordatabase.com/investors/andreessen-horowitz-a16z/ |
| Richmond Global | VC firm | Las Vegas, NV | Growth | Biotech, AI, Cybersecurity, Govtech |  | $116M (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/richmond-global/ |
| Accelmed | VC firm | Aventura, FL | Growth | Biotech, Healthtech, Developer Tools, Medtech | Portfolio news, Apr 2026 | $401M (SEC Form D, 2021) | 2026-11-05 | https://theinvestordatabase.com/investors/accelmed/ |
| B Capital | VC firm | Manhattan Beach, CA | Seed, Series A, Series B, Growth | Biotech, AI, Fintech, Healthtech | New fund, Jul 2025 | $307M (SEC Form D, 2023) | 2026-11-04 | https://theinvestordatabase.com/investors/b-capital/ |
| DC Global Ventures | VC firm | Menlo Park, CA | Seed, Growth | Biotech, Healthtech, Industrial Tech, Medtech |  | $2.7B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/dc-global-ventures/ |
| NW Angel Fund | VC firm | Seattle, WA | Growth | Biotech, Healthtech, SaaS, Medtech | New fund, Feb 2024 | $5M (SEC Form D, 2024) | 2026-11-05 | https://theinvestordatabase.com/investors/nw-angel-fund/ |
| Antler | Accelerator | New York, NY | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Healthtech, Consumer | New deal, Aug 2026 | $90M (SEC Form D, 2023) | 2026-11-04 | https://theinvestordatabase.com/investors/antler/ |
| Apple Tree Venture | VC firm | New York, NY | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | Portfolio news, Sep 2025 | $3.5B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/apple-tree-venture/ |
| Frazier Life Sciences | VC firm | Palo Alto, CA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, Healthtech | New fund, Mar 2025 | $7.0B (SEC Form ADV) | 2026-11-05 | https://theinvestordatabase.com/investors/frazier-life-sciences/ |

You are seeing 22 of 44. The full list adds 22 more investors and 251 named decision-makers.

Get all 44 investors and 251 named contacts, $49, one-time: https://theinvestordatabase.com/buy/list/growth-biotech-investors-us
This page: https://theinvestordatabase.com/lists/growth-biotech-investors-us/

## Method and limits
- Source: All 44 rows carry an SEC filing (Form D or Form ADV). All 44 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule: Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at growth-stage.
- Order: Activity score out of 100: recency of the latest fund filing or dated deal (30: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (20; half of that when the sector is stated only), stage focus (15: all of it when growth-stage is the only stage the firm states, split evenly when it states more), stated focus on the US (15: full marks when the firm names the US as where it invests, half when it says global), size of the fund on file on a log scale (12) and completeness of the public record (8). Stage and regional focus are our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Fill rates: Of 44 rows: stage 44, sector 44, fund size 39, website 44. In the paid file: named decision-makers on 42 rows, firm email on 17, LinkedIn page on 21, check size on 3.

## Questions
### How many growth-stage biotech investors in the US are there?
We list 44 as of November 2026. 23 of the 44 have a fund filing or a dated deal in the last 12 months. The cities with the most are New York (7), Menlo Park (3) and Boston (3).

### Which growth-stage biotech investors in the US raised a new fund in the last 12 months?
15 of the 44 have a fund filing dated in the last 12 months. The most recent on this list are Audere (Oct 2026), K5 Global (Oct 2026) and NewVale Capital (Oct 2026).

### What is the typical fund size of growth-stage biotech investors in the US?
The median fund size on file for this list is $100M, across the 26 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 18 do not disclose a size there.

### How do I contact growth-stage biotech investors in the US?
The paid file holds 251 named decision-makers across 42 of these 44 and a firm email for 17. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.

### Where does the data on growth-stage biotech investors in the US come from?
All 44 rows have an SEC filing on file (Form D or Form ADV). Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 6 Nov 2026 at the latest. The whole file is re-verified twice a year.